Lu Xiangdong, Zhang Yao, Pan Yukai, Cao Minmin, Zhou Xie, Zhang Tingrong
Department of Oncology, The Jiangyin Hospital Affiliated to Medical College of Southeast University, Jiangyin, Jiangsu 214400, P.R. China.
Oncol Lett. 2021 Jan;21(1):40. doi: 10.3892/ol.2020.12301. Epub 2020 Nov 13.
COOH-terminus tensin-like molecule (CTEN) is a member of the tensin family, which is considered to be one of the novel proto-oncogenes involved in tumorigenesis and cancer progression. However, the mechanisms of CTEN in acquired resistance of non-small cell lung cancer (NSCLC) remain relatively unknown. The aim of the present study was to understand the roles of CTEN in acquired gefitinib resistance of NSCLC. The present study investigated the expression level of CTEN using reverse transcription-quantitative polymerase chain reaction and Western blot analysis. Cell Counting kit-8 and colony-formation assays were performed to evaluate the proliferative and colony-formative abilities of PC9 and PC9/GR cells . Mouse xenograft models were used to assess the growth of PC9/GR cells . A gefitinib-resistant NSCLC cell line (PC9/GR) was established, and the protein and mRNA expression levels of CTEN were observed to be higher in PC9/GR cells than in PC9 cells. Notably, the sensitivity of PC9/GR cells to gefitinib was observed to be decreased when CTEN was overexpressed, while PC9/GR cells with CTEN-downregulation showed markedly enhanced sensitivity to gefitinib. proliferation and colony formation assays revealed that increased CTEN markedly promoted the cell proliferative and colony-forming capacities of PC9 and PC9/GR cells, and CTEN-silencing inhibited the cell proliferative and colony-forming abilities of the PC9 and PC9/GR cells. Notably, deficient expression of CTEN notably retarded the growth of PC9/GR xenografts . In addition, the plasma mRNA expression of CTEN was notably elevated in patients with NSCLC with acquired gefitinib resistance. Overexpression of CTEN is associated with acquired gefitinib resistance in NSCLC. CTEN may be investigated as a potential therapeutic target for the treatment of patients with NSCLC with acquired gefitinib resistance.
羧基末端张力蛋白样分子(CTEN)是张力蛋白家族的成员,被认为是参与肿瘤发生和癌症进展的新型原癌基因之一。然而,CTEN在非小细胞肺癌(NSCLC)获得性耐药中的机制仍相对不清楚。本研究的目的是了解CTEN在NSCLC获得性吉非替尼耐药中的作用。本研究使用逆转录定量聚合酶链反应和蛋白质免疫印迹分析来检测CTEN的表达水平。采用细胞计数试剂盒-8和集落形成试验来评估PC9和PC9/GR细胞的增殖和集落形成能力。使用小鼠异种移植模型来评估PC9/GR细胞的生长情况。建立了吉非替尼耐药的NSCLC细胞系(PC9/GR),观察到PC9/GR细胞中CTEN的蛋白质和mRNA表达水平高于PC9细胞。值得注意的是,当CTEN过表达时,观察到PC9/GR细胞对吉非替尼的敏感性降低,而CTEN下调的PC9/GR细胞对吉非替尼的敏感性显著增强。增殖和集落形成试验表明,CTEN的增加显著促进了PC9和PC9/GR细胞的增殖和集落形成能力,而CTEN沉默则抑制了PC9和PC9/GR细胞的增殖和集落形成能力。值得注意的是,CTEN的表达缺陷显著抑制了PC9/GR异种移植瘤的生长。此外,在获得性吉非替尼耐药的NSCLC患者中,CTEN的血浆mRNA表达显著升高。CTEN的过表达与NSCLC获得性吉非替尼耐药有关。CTEN可作为治疗获得性吉非替尼耐药NSCLC患者的潜在治疗靶点进行研究。